Oncology Institute (NASDAQ:TOI) Director Brad Hively Sells 13,333 Shares of Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Brad Hively sold 13,333 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $3.77, for a total value of $50,265.41. Following the transaction, the director directly owned 683,721 shares of the company’s stock, valued at $2,577,628.17. The trade was a 1.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Oncology Institute Stock Up 1.9%

Shares of NASDAQ:TOI opened at $3.84 on Wednesday. The company has a quick ratio of 1.39, a current ratio of 1.68 and a debt-to-equity ratio of 14.58. The company has a market capitalization of $377.78 million, a P/E ratio of -6.00 and a beta of 0.16. The Oncology Institute, Inc. has a 52-week low of $0.17 and a 52-week high of $4.88. The stock’s fifty day simple moving average is $3.74 and its 200-day simple moving average is $3.41.

Oncology Institute (NASDAQ:TOI) last announced its earnings results on Thursday, November 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The firm had revenue of $136.56 million during the quarter, compared to analyst estimates of $122.63 million. Oncology Institute had a negative net margin of 13.21% and a negative return on equity of 1,527.21%.

Institutional Investors Weigh In On Oncology Institute

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TOI. ProShare Advisors LLC purchased a new position in Oncology Institute in the 2nd quarter valued at about $25,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Oncology Institute in the second quarter worth about $32,000. Cetera Investment Advisers boosted its holdings in Oncology Institute by 35.0% in the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock valued at $36,000 after purchasing an additional 4,545 shares during the last quarter. State of Wyoming purchased a new position in Oncology Institute in the second quarter valued at about $37,000. Finally, Prelude Capital Management LLC acquired a new stake in Oncology Institute during the 3rd quarter valued at approximately $41,000. Hedge funds and other institutional investors own 36.86% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TOI shares. Needham & Company LLC began coverage on shares of Oncology Institute in a research note on Tuesday, November 25th. They set a “buy” rating and a $5.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research note on Wednesday, October 8th. Finally, BTIG Research reissued a “buy” rating and issued a $7.00 price objective on shares of Oncology Institute in a research report on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Oncology Institute has a consensus rating of “Moderate Buy” and an average price target of $6.50.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.